Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levonorgestrel + ethinylestradiol
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Loette Diario is a low-dose combined oral contraceptive (COC) containing the synthetic progestin levonorgestrel (100 mcg) and the synthetic estrogen ethinylestradiol (20 mcg). Marketed by Pfizer, it is provided in a 28-day 'Diario' (daily) format consisting of 21 active pink film-coated tablets and 7 white placebo tablets to ensure continuous daily administration. The drug's primary mechanism involves the suppression of ovulation by inhibiting the release of gonadotropins (LH and FSH) from the pituitary gland. Additionally, it increases the viscosity of cervical mucus to impede sperm transport and alters the endometrial lining to prevent implantation. While primarily indicated for contraception, Loette Diario is also used to manage conditions such as polycystic ovary syndrome (PCOS), acne, and dysmenorrhea. It has been utilized in Phase III clinical trials as a comparator arm to evaluate cardiometabolic health markers in adolescent girls with hyperinsulinemic ovarian androgen excess.
- Brand names
- Loette DiarioLoette
- Other names
- Levonorgestrel/Ethinylestradiol 100/20Combined oral contraceptive
02
Targets
RB1 (Retinoblastoma-associated Protein)PR-A (Progesterone Receptor A)ESR1 (ERα)AR (Adrenergic receptors)ESR2 (ERβ)
Beyond the preview
Go deeper on levonorgestrel + ethinylestradiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levonorgestrel + ethinylestradiol.